Satoru Furuhashi1, Yoshifumi Morita2, Shinya Ida1, Ryuta Muraki1, Ryo Kitajima1, Katsunori Suzuki1, Makoto Takeda1, Hirotoshi Kikuchi1, Yoshihiro Hiramatsu1,3, Kiyotaka Kurachi1, Yoji Shido4, Ken Sugimoto5, Hiroaki Ito6, Yuichiro Maekawa7, Hiroyuki Mineta8, Hideaki Miyake9, Hiroya Takeuchi1. 1. Second Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan. 2. Second Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan; yoshi-mo@hama-med.ac.jp. 3. Department of Perioperative Functioning Care and Support, Hamamatsu University School of Medicine, Hamamatsu, Japan. 4. Department of Orthopaedic Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan. 5. First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan. 6. Department of Obstetrics and Gynecology, Hamamatsu University School of Medicine, Hamamatsu, Japan. 7. Internal Medicine III, Hamamatsu University School of Medicine, Hamamatsu, Japan. 8. Department of Otorhinolaryngology/Head and Neck Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan. 9. Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Abstract
BACKGROUND: We sought to identify the risk factors of totally implantable central venous access port (TICVAP)-related infections in patients with malignant disease. PATIENTS AND METHODS: Overall, 324 consecutive patients who received a TICVAP at our institution were retrospectively analysed. We further analysed cases of TICVAP-related complications. The risk factors for TICVAP-related infection were investigated using Cox regression hazard models. RESULTS: With a median TICVAP duration of 268 days (range=1-1,859 days), TICVAP-related complications were observed in 36 cases and infectious complications in late phase were the most common, seen in 19 cases (9.26%). A multivariate analysis showed that patients with head and neck malignancy (p<0.001) and patients who received TICVAP insertion in the upper arm (p<0.001) were independently at a higher risk for TICVAP-related infections. CONCLUSION: Patients with head and neck malignancy or TICVAP insertion in the upper arm have potentially increased risk for late-phase TICVAP-related infections.
BACKGROUND: We sought to identify the risk factors of totally implantable central venous access port (TICVAP)-related infections in patients with malignant disease. PATIENTS AND METHODS: Overall, 324 consecutive patients who received a TICVAP at our institution were retrospectively analysed. We further analysed cases of TICVAP-related complications. The risk factors for TICVAP-related infection were investigated using Cox regression hazard models. RESULTS: With a median TICVAP duration of 268 days (range=1-1,859 days), TICVAP-related complications were observed in 36 cases and infectious complications in late phase were the most common, seen in 19 cases (9.26%). A multivariate analysis showed that patients with head and neck malignancy (p<0.001) and patients who received TICVAP insertion in the upper arm (p<0.001) were independently at a higher risk for TICVAP-related infections. CONCLUSION:Patients with head and neck malignancy or TICVAP insertion in the upper arm have potentially increased risk for late-phase TICVAP-related infections.